Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization

Vaccine

Volumn 25, Issue 22, 2007, Pages 4487-4501

  Bermúdez, Adriana ^a   Reyes, Claudia ^a   Guzmán, Fanny ^a   Vanegas, Magnolia ^a   Rosas, Jaiver ^a,b   Amador, Roberto ^a,b   Rodríguez, Raul ^a   Patarroyo, Manuel Alfonso ^a,b   Patarroyo, Manuel Elkin ^a,b  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

DC; HPLC; Immunogenicity; Malaria; MALDI TOF; NMR; SPf66

Indexed keywords

MALARIA VACCINE; PLACEBO; QS 21; TETANUS TOXOID;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DRUG COST; DRUG SAFETY; DRUG STABILITY; HUMAN; HYPERSENSITIVITY REACTION; MALARIA; MONKEY; NONHUMAN; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; TETANUS;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; AOTIDAE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS; FEMALE; HUMANS; INFANT; MAGNETIC RESONANCE SPECTROSCOPY; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VACCINES, SYNTHETIC;

EID: 34247611891     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.03.016     Document Type: Article

References (32)

1. Patarroyo M.E., Romero P., Torres M.L., Clavijo P., Moreno A., Martinez A., et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328 (1987) 629-632
2. Patarroyo M.E., Amador R., Clavijo P., Moreno A., Guzman F., Romero P., et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332 (1988) 158-161
3. Rodríguez R., Moreno A., Guzmán F., Calvo M., and Patarroyo M.E. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. Am J Trop Med Hyg 43 (1990) 339-354
4. White N., Nosten F., Bjorkman A., Marsh K., and Snow R.W. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363 (2004) 1160
5. Merrifield R.B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 85 (1963) 2149-2154
6. Houghten R.A. General method for the rapid solid phase synthesis of large numbers of peptides: specificity of antigen antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 82 (1985) 5131-5135
7. Bodanszky M. Principles of Peptide Synthesis (1984), Wiley InterScience, Berlin/Heildelberg/NY
8. Ruebush II T.K., Campbell G.H., Moreno A., Patarroyo M.E., and Collins W.E. Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens. Am J Trop Med Hyg 43 (1990) 355-366
9. Amador R., Moreno A., Murillo L.A., Sierra O., Saavedra D., Rojas M., et al. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J Infect Dis 166 (1992) 139-144
10. Amador R., Moreno A., Valero V., Murillo L., Mora A.L., Rojas M., et al. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity. Vaccine 10 (1992) 179-184
11. Patarroyo G., Franco L., Amador R., Murillo L.A., Rocha C.L., Rojas M., et al. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Vaccine 10 (1992) 175-178
12. Valero M.V., Amador L.R., Galindo C., Figueroa J., Bello M.S., Murillo L.A., et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341 (1993) 705-710
13. Alonso P.L., Smith T., Armstrong Schellenberg J.R.M., Masanja H., Mwankusye S., Urassa H., et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344 (1994) 1175-1181
14. Sempertegui F., Estrella B., Moscoso J., Piedrahita L., Hernandez D., Gaybor J., et al. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 12 (1994) 337-342
15. Noya O., Berti Y.G., Alarcon de Noya B., Borges R., Zerpa N., Urbaez J.D., et al. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis 170 (1994) 396-402
16. Leach A., Drakeley C.J., D'Alessandro U., Fegan G.W., Bennett S., Ballou W.R., et al. A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants. Parasite Immunol 17 (1995) 441-444
17. Valero M.V., Amador R., Aponte J.J., Narvaez A., Galindo C., Silva Y., et al. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine 14 (1996) 1466-1470
18. Salcedo M., Barreto L., Rojas M., Moya R., Cote J., and Patarroyo M.E. Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol 84 (1991) 122-128
19. Campbell G.H., Aley S.B., Ballou W.R., Hall T., Hockmeyer W.T., Hoffman S.L., et al. Use of synthetic and recombinant peptides in the study of host-parasite interactions in the malarias. Am J Trop Med Hyg 37 (1987) 428-444
20. Lambros C., and Vanderberg J.P. Synchronization of Plasmodium falciparum erythrocyte stages in culture. J Parasitol 65 (1979) 418-420
21. Blake M.S., Johnston K.H., Rusell-Jones G.J., and Gotschlich E.C. A rapid sensitive method for detection of alkaline Phosphatase conjugated antibody on Western Blot. Anal Biochem 136 (1984) 175-179
22. Alder A.J., Greenfield N.J., and Fasman G.D. Circular dichroism and optical rotary dispersion of proteins and polypeptides. Meth Enzymol 27 (1973) 675
23. Rance M., Soressen O.W., Bodenhausen G., Wagner G., Ernst R.R., and Wüthrich K. Improved spectral resolution in cosy 1H NMR spectra of proteins via double quantum filtering. Biochem Biophys Res Commun 117 (1983) 479-485
24. Bax A., and Davis D.G. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. J Magn Reson 65 (1985) 355-360
25. Jeener J., Meier B.H., Backman P., and Ernst R.R. Investigation of exchange processes by two-dimensional NMR spectroscopy. J Chem Phys 71 (1979) 4546-4553
26. Wüthrich K. NMR of Proteins and Nucleic Acids (1986), John Wiley & Sons, New York p. 117-29
27. Kensil C.R. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 13 (1996) 1-55
28. Kashala O., Amador R., Valero M.V., Moreno A., Barbosa A., Nickel B., et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 20 (2002) 2263-2277
29. Heppner D.G., Cummings J.F., Ockenhouse C., Kester K.E., Lyon J.A., and Gordon D.M. New World monkey efficacy trials for malaria vaccine development: critical path or detour?. Trends Parasitol 17 (2001) 419-425
30. Alonso P.L., Smith T.A., Armstrong-Schellenberg J.R., Kitua A.Y., Masanja H., Hayes R., et al. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. J Infect Dis 174 (1996) 367-372
31. Nosten F., Luxemburger C., Kyle D.E., Ballou W.R., Wittes J., Wah E., et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in north-western Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 348 (1996) 701-707
32. Murillo L.A., Rocha C.L., Mora A.L., Kalil J., Goldenberg A.K., and Patarroyo M.E. Molecular analysis of HLA DR4-beta 1 gene in malaria vaccinees. Typing and subtyping by PCR technique and oligonucleotides. Parasite Immunol 13 (1991) 201-210